Edwin is a highly respected executive with over 30 years’ experience in the life sciences sector. Most recently, he spent 12 years as Chief Executive Officer (CEO) of Ablynx, which was acquired by Sanofi for $4.8bn in June 2018, delivering significant shareholder value and overseeing approval of its first product, indicated for a rare blood disease. During his tenure, he led two successful IPOs on EuroNext and NASDAQ respectively, as well as presiding over workforce growth from fifty people to almost five hundred. Before this, he was CEO and Executive Chairman of Oxford Asymmetry International (OAI) where he oversaw a series of venture rounds and an IPO on the London Stock Exchange, valuing the company at £120m. In 2000, Edwin led the £316m merger of OAI with Evotec Biosystems. Between Ablynx and OAI, Edwin has successfully raised over €500m in equity and debt financing. Furthermore, Edwin has more than 25 years of Board level experience with more than 10 other European life sciences companies, where he has advised on broad and multiple growth strategies including venture capital fundraisings, IPOs and acquisitions. Today he is also Chairman of Achilles Therapeutics and Virion Biotherapeutics. Edwin obtained his Ph.D. in Chemistry from Sheffield University.